NovoCurmin

NovoCurmin is a reformulated curcumin complex protected by 2 international patent applications. It is both a standalone B2B ingredient platform AND the curcumin technology used inside ImmuCurc, GeLiPthin-1, and Cortexa.

KEY SPECIFICATIONS: Water solubility 89 mg/mL (vs standard curcumin extract ~1–2 mg/mL = ~45–89× improvement). Uses GRAS excipients accepted by major global regulatory authorities. Available as powder or liquid ready-to-fill formats. Suitable for supplements, pharmaceuticals, beverages, and food applications.

TECHNOLOGY: Uses Micro Matrix Technology to create a micronized curcuminoid complex embedded in a self-emulsifying matrix. The composition enables curcumin to dissolve rapidly in aqueous environments — critical because curcumin's notoriously poor water solubility is the primary barrier to oral bioavailability.

MANUFACTURING: cGMP manufacturing. Higher curcumin loading per mg than competing technologies. Lower emulsifier use than liposomal or nano-emulsion approaches. DMF (Drug Master File) extract quality. Premix or finished dosage form options.

THE CURCUMIN PROBLEM: Curcumin has been the subject of >15,000 published studies showing diverse biological activities. Yet standard curcumin has <1% oral bioavailability due to: poor water solubility, rapid intestinal metabolism, rapid systemic clearance, and chemical instability at physiological pH. NovoCurmin addresses all four barriers simultaneously.

MICRONIZATION: Standard curcumin extract particles are 50–200 µm. NovoCurmin micronizes to <10 µm, dramatically increasing surface area available for dissolution. Greater surface area = faster dissolution = more curcumin available for absorption before intestinal transit moves it past the absorption window.

SELF-EMULSIFYING MATRIX: The polysorbate-based matrix creates spontaneous micelle formation in GI fluids. Curcumin molecules are trapped inside these micelles and presented directly to the intestinal epithelium in a pre-solubilised form.

STABILITY PROTECTION: Curcumin degrades rapidly at pH >7 (intestinal conditions). The Micro Matrix encapsulation provides a protective microenvironment that shields curcumin from alkaline degradation during transit, releasing it at the absorption site in its active form.

METABOLIC PROTECTION: The matrix composition includes components that modulate Phase II metabolism (glucuronidation/sulfation) — the primary clearance pathway for curcumin. This extends the systemic half-life and increases the proportion of free (unconjugated) curcumin in plasma.

COMPARISON TO COMPETING TECHNOLOGIES: Phytosomal curcumin (Meriva/Longvida): uses phospholipid complexation; moderate improvement but expensive. Cyclodextrin curcumin: uses molecular encapsulation; good solubility but limited loading capacity. Nano-emulsion curcumin: liquid format; unstable, requires cold chain. NovoCurmin: solid-state, self-emulsifying, highest solubility (89 mg/mL), stable at room temperature, 3+ year shelf life.

Key takeaway: NovoCurmin doesn't just improve one aspect of curcumin delivery — it addresses solubility, stability, metabolism, and absorption simultaneously through the integrated Micro Matrix approach.

SOLUBILITY COMPARISON (mg/mL): NovoCurmin ~89 | Competitor 1 ~21 | Competitor 2 ~25 | Competitor 3 ~22 | Competitor 4 ~9 | Standard curcumin extract ~1–2. NovoCurmin leads the category by 3.5–10× over the nearest competitor.

BIOAVAILABILITY (Preclinical PK Data): NovoCurmin Powder — Cmax: 31,322 ng/mL, Tmax: 1h, AUC₀₋₈ₕ: 84,440 h·ng/mL. Curcumin API — Cmax: 2,199 ng/mL, Tmax: 0.5h, AUC: 9,606. Phytosome Competitor — Cmax: 5,794, Tmax: 8h, AUC: 28,711. Gamma-cyclodextrin Competitor — Cmax: 13,053, Tmax: 4h, AUC: 74,058.

FOLD IMPROVEMENTS vs Curcumin API: NovoCurmin ~14× Cmax, ~8.8× AUC. vs Phytosome: ~5.4× Cmax, ~2.9× AUC. vs Gamma-cyclodextrin: ~2.4× Cmax, ~1.14× AUC.

PHARMACOKINETIC PROFILE: NovoCurmin shows a sharp peak at 0.5–1 hour followed by gradual decline — indicating rapid absorption with sustained systemic presence. Competitors peak much later (4–8 hours) and lower, suggesting slower, less efficient absorption.

Important: These are preclinical pharmacokinetic studies. They demonstrate superior absorption characteristics but are not human clinical efficacy trials. The data supports the delivery technology claim but does not prove therapeutic outcomes in humans.

IMMUCURC: Contains NovoCurmin as the curcumin pillar of the three-active immune support formula. The micronized curcumin helps support healthy inflammatory response as part of the gut-immune system. Delivered in a delayed-release capsule for intestinal targeting.

GELIPTHIN-1: Contains Micronized Curcumin (NovoCurmin technology) within the Multi-Path Satiety Blend. Curcumin supports healthy inflammatory response — relevant because chronic low-grade inflammation is associated with metabolic dysfunction and appetite dysregulation.

CORTEXA: Contains Micronized Curcumin (NovoCurmin technology) within the NeuroPro-Autophagy Support Blend. Curcumin's neuroprotective properties are well-published; the micronized form ensures meaningful systemic levels reach neural tissue.

B2B LICENSING: Beyond MN Nutra's own products, NovoCurmin is available for licensing to manufacturers worldwide. Applications include: joint health supplements, sports nutrition, beauty-from-within, cardiovascular support, and pharmaceutical development.

Key takeaway: NovoCurmin is the curcumin technology spine running through multiple MN Nutra products. When explaining any product containing curcumin, you can reference the NovoCurmin platform data to substantiate the delivery advantage.

APPROVED CLAIMS: 'Patent-protected curcumin delivery system with 89 mg/mL water solubility' | 'Preclinical data showing up to 14× higher Cmax vs standard curcumin' | 'Outperforms phytosomal and cyclodextrin curcumin technologies in preclinical PK' | 'GRAS excipients, cGMP manufacturing' | 'The curcumin technology inside ImmuCurc, GeLiPthin-1, and Cortexa'

PROHIBITED CLAIMS: 'Treats inflammation, arthritis, or any disease' | 'Anti-cancer properties' | 'FDA approved' | '14× more effective' (absorption ≠ efficacy) | 'Clinically proven in humans' (PK data is preclinical) | 'Cures joint pain' | 'Anti-aging miracle'

COMMERCIAL POSITIONING: NovoCurmin solves the fundamental problem with curcumin supplements — most products have negligible bioavailability despite curcumin's extensive published biological activity. NovoCurmin achieves industry-leading solubility and absorption, making it the ideal platform for products where actual systemic delivery matters.

Key takeaway: NovoCurmin is the curcumin platform technology. The preclinical PK data is strong but must be clearly labelled as preclinical, not human clinical. Position it as 'the delivery technology that makes curcumin actually reach the bloodstream.'

Required FDA Disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'